Skip to main content
OpenTrials
Completed

NCT Number: NCT00767806

A Study for Patient With Chronic Low Back Pain

The purpose of this study is to determine if duloxetine reduces the severity of chronic low back pain.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sacomã, Brazil

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female outpatients with chronic low back pain

Exclusion criteria

  • Cardiovascular, hepatic, renal, respiratory, or hematologic illness, or other medical or psychiatric condition that, in the opinion of the investigator, would compromise participation or be likely to lead to hospitalization during the course of the study.
  • Acute liver injury (such as hepatitis) or severe cirrhosis.
  • Previous exposure to duloxetine.
  • Body Mass Index (BMI) over 40.
  • Major depressive disorder.
  • Daily use of narcotics.

Treatment and study plan

Duloxetine

Drug

60 mg orally once daily for 12 weeks

Other names: Cymbalta, LY248686

Placebo

Drug

Placebo once daily orally for 12 weeks

Primary outcomes

  1. Change From Baseline to 12 Weeks in Brief Pain Inventory 24-hour Average Pain Score

    Time frame: baseline, 12 weeks

    A self-reported scale that measures the severity of pain based on the average pain over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). Least Squares Mean values were controlled for investigator and baseline severity.

Secondary outcomes

  1. Change From Baseline to 12 Weeks on the Brief Pain Inventory - Severity (BPI-S) and Interference (BPI-I)

    Time frame: baseline, 12 weeks

    BPI-S and BPI-I are self-reported scales measuring severity of pain and interference on function. Severity scores: 0 (no pain) to 10 (severe pain) on each question assessing worst pain, least pain in past 24 hours, and pain right now. Interference scores: 0 (does not interfere) to 10 (completely interferes) on each question assessing interference of pain in past 24 hours for general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Average interference = average of non-missing scores of individual interference items.

  2. Change From Baseline to 12 Weeks in Weekly Mean of 24-hour Average Pain, Worst Pain, and Night Pain Rating

    Time frame: baseline, 12 weeks

    24-hour average pain severity scores were recorded daily on an 11-point Likert scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain). Patients completed the electronic diary at bedtime. The 11-point Likert scale was also used for assessment of night pain and worst pain each day, and evaluated as weekly means. Least Squares Mean values were controlled for investigator and baseline severity.

  3. Number of Responders: 30 Percent (%) or Greater Reduction of the Brief Pain Inventory (BPI) Average Pain Severity Rating at 12 Week Endpoint

    Time frame: 12 weeks

    Response to treatment was defined as at least a 30% reduction from baseline to endpoint (last observation carried forward) in the BPI average pain severity score. BPI is a self-reported scale that measures the severity of pain based on the average pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). Response was assessed at endpoint.

  4. Number of Responders: 50 Percent (%) or Greater Reduction of the Brief Pain Inventory (BPI) Average Pain Severity Rating at 12 Week Endpoint

    Time frame: 12 weeks

    Response to treatment was defined as at least a 50% reduction from baseline to endpoint (last observation carried forward) in the BPI average pain severity score. BPI is a self-reported scale that measures the severity of pain based on the average pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). Response was assessed at endpoint.

  5. Number of Sustained Responders at 12 Week Endpoint

    Time frame: 12 weeks

    Sustained responders: participants with ≥30% reduction of BPI average pain rating from baseline to endpoint and baseline to earlier visit than last visit and who maintain a ≥20% reduction of BPI average pain rating from baseline at every visit between last visit and earlier visit. BPI: a self-reported scale that measures the severity of pain based on the average pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). Number of sustained responders was assessed at endpoint.

  6. Number of Participants Reaching Each Threshold of of BPI Average Pain Score Reduction During the Study - Cumulative Distribution

    Time frame: 12 weeks

    The results presented are the cumulative number of participants reaching each threshold of BPI average pain reduction. The thresholds are given as percent reductions in BPI average pain score from the baseline score. BPI: a self-reported scale that measures the severity of pain based on the average pain over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). Number of participants under each threshold was assessed at endpoint.

  7. Change From Baseline to 12 Weeks Endpoint in Clinical Global Impressions of Severity (CGI-S)

    Time frame: baseline, 12 weeks

    Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Least Squares Mean values were controlled for investigator and baseline severity.

  8. Patient's Global Impression of Improvement (PGI-I) at 12 Weeks

    Time frame: 12 weeks

    A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse). Least Squares Mean values were controlled for investigator and baseline severity.

  9. Change From Baseline to 12 Weeks in Roland Morris Disability Questionnaire

    Time frame: baseline, 12 weeks

    Roland-Morris questionnaire will be completed by the patient and measures the degree of disability due to back pain. The questionnaire consists of 24 statements and the patient is instructed to put a mark next to each appropriate statement. The number of statements marked will be added up by the clinician and a total score is given. The total score ranges from 0 (no disability) to 24 (severe disability). Least Squares Mean values were controlled for investigator and baseline severity.

  10. Change From Baseline to 12 Weeks in Profile of Mood States - Brief Form

    Time frame: baseline, 12 weeks

    The 30-item BPOMS measures mood states and has 6 factors: tension-anxiety (Ten), depression-dejection (Dep), anxiety-hostility (Ang), fatigue (Fat), confusion (Con), and vigor (Vig). Item scores: 0 (not at all) to 4 (extremely). Each factor scores range from 0 to 20. The Total score is sum of all factor scores minus the factor score for vigor (Total=Ten+Dep+Ang+Fat+Con-Vig) and ranges from 0 (least disturbed) to 80 (most disturbed).

  11. Change From Baseline to 12 Weeks in 36-item Short-Form (SF-36) Health Survey

    Time frame: baseline, 12 weeks

    The SF-36 Health Status Survey is a generic, health-related scale assessing subjects' quality of life on 8 domains: physical functioning, social functioning, bodily pain, vitality, mental health, role-physical, role-emotional and general health and 2 summary scores (mental component summary [MCS] and physical component summary [PCS]). The score for each of the domain and component summary=0-100 (higher scores indicate better health status or functioning).

  12. Change From Baseline to 12 Weeks in European Quality of Life Questionnaire - 5 Dimension

    Time frame: baseline, 12 weeks

    Generic, multidimensional, health-related, quality-of-life instrument. The profile allows patients to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood. A single score between 1 and 3 is generated for each domain. For each patient, the outcome rating on 5 domains will be mapped to a single index through an algorithm. The index ranges between 0 and 1; higher scores indicate a better health state perceived by the patient. Participants were evaluated with the United Kingdom (UK) and the United States (US) population based index score.

  13. Change From Baseline to 12 Weeks in Work Productivity and Activity Impairment Instrument (WPAI)

    Time frame: baseline, 12 weeks

    WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment.

    • Absenteeism
    • Presenteeism
    • Work productivity loss
    • Activity Impairment Scores range from 0 to 1 for each of the above 4 types; higher scores indicate greater impairment.
  14. Participants Who Discontinued From Baseline to 12 Weeks

    Time frame: baseline, 12 weeks

    Reasons for discontinuation are listed in the participant flow.

  15. Change From Baseline to 12 Weeks in Uric Acid

    Time frame: baseline, 12 weeks

    Least Squares Mean values were controlled for investigator.

  16. Change From Baseline to 12 Week Endpoint in Albumin

    Time frame: baseline, 12 weeks

    Least Squares Mean values were controlled for investigator.

  17. Change From Baseline to 12 Week Endpoint in Alkaline Phosphatase

    Time frame: baseline, 12 weeks

    Least Squares Mean values were controlled for investigator.

  18. Change From Baseline to 12 Week Endpoint in Alanine Aminotransferase

    Time frame: baseline, 12 weeks

    Least Squares Mean values were controlled for investigator.

  19. Change From Baseline to 12 Week Endpoint in Aspartate Aminotransferase

    Time frame: baseline, 12 weeks

    Least Squares Mean values were controlled for investigator.

  20. Change From Baseline to 12 Week Endpoint in Creatinine

    Time frame: baseline, 12 weeks

    Least Squares Mean values were controlled for investigator.

  21. Change From Baseline to 12 Week Endpoint in Total Protein

    Time frame: baseline, 12 weeks

    Least Squares Mean values were controlled for investigator.

  22. Change From Baseline to 12 Weeks in Blood Pressure

    Time frame: baseline, 12 weeks

    Least Squares Mean values were controlled for investigator.

  23. Change From Baseline to 12 Week Endpoint in Weight

    Time frame: baseline, 12 weeks

    Least Squares Mean values were controlled for investigator.

  24. Change From Baseline to 12 Week Endpoint in Pulse Rate

    Time frame: baseline, 12 weeks

    Least Squares Mean values were controlled for investigator.

  25. Number of Participants With Suicidal Ideation or Suicidal Behaviors According to the Columbia Suicide Severity Rating Scale

    Time frame: baseline through 12 weeks

    The Columbia Suicide Severity Rating Scale (C-SSRS) captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The scale includes suggested questions to solicit the type of information needed to determine if a suicide-related thought or behavior occurred.

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Registry information

Official study title

Effect of Duloxetine 60 mg Once Daily Versus Placebo in Patients With Chronic Low Back Pain

Important dates

Study start
2008
Primary completion
2009
Study completion
2009
First posted
Oct 7, 2008
Registry last updated
Oct 18, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.